Holen Sie sich die Stockscreener-App
54.26
0.71%
-0.39
Handel nachbörslich:
54.31
0.05
+0.09%
Schlusskurs vom Vortag:
$54.65
Offen:
$55.5
24-Stunden-Volumen:
1.35M
Relative Volume:
0.67
Marktkapitalisierung:
$5.17B
Einnahmen:
$170.10M
Nettoeinkommen (Verlust:
$-239.59M
KGV:
-19.38
EPS:
-2.8
Netto-Cashflow:
$-191.20M
1W Leistung:
+3.14%
1M Leistung:
-1.49%
6M Leistung:
-16.21%
1J Leistung:
+29.65%
1-Tages-Spanne:
$53.57
$56.69
1-Wochen-Bereich:
$51.80
$60.86
52-Wochen-Spanne:
$30.04
$78.48
Crispr Therapeutics Ag Stock (CRSP) Company Profile
Firmenname
Crispr Therapeutics Ag
Sektor
Branche
Telefon
(617) 315-4600
Adresse
BAARERSTRASSE 14, ZUG
Vergleichen Sie CRSP mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CRSP
Crispr Therapeutics Ag
|
54.26 | 5.21B | 170.10M | -239.59M | -191.20M | -2.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.17 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.25 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
864.42 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
354.75 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
336.16 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Crispr Therapeutics Ag Stock (CRSP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-18 | Eingeleitet | JP Morgan | Overweight |
| 2025-02-14 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2025-02-12 | Hochstufung | TD Cowen | Sell → Hold |
| 2025-02-03 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-08-06 | Bestätigt | Needham | Buy |
| 2024-08-02 | Eingeleitet | Rodman & Renshaw | Buy |
| 2024-06-28 | Fortgesetzt | Guggenheim | Neutral |
| 2024-02-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2023-12-11 | Herabstufung | TD Cowen | Market Perform → Underperform |
| 2023-10-17 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-09-27 | Eingeleitet | Mizuho | Buy |
| 2023-08-17 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-05-30 | Eingeleitet | William Blair | Outperform |
| 2023-04-13 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-03-21 | Eingeleitet | Bernstein | Mkt Perform |
| 2023-03-17 | Eingeleitet | Bryan Garnier | Buy |
| 2023-03-07 | Eingeleitet | Robert W. Baird | Neutral |
| 2022-10-11 | Eingeleitet | Morgan Stanley | Underweight |
| 2022-08-09 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2022-06-23 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-06-17 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-04-28 | Eingeleitet | Credit Suisse | Neutral |
| 2021-12-07 | Eingeleitet | Cowen | Market Perform |
| 2021-10-19 | Eingeleitet | SVB Leerink | Outperform |
| 2021-06-14 | Hochstufung | Citigroup | Sell → Neutral |
| 2021-04-21 | Hochstufung | Jefferies | Hold → Buy |
| 2021-03-04 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2020-12-10 | Bestätigt | Chardan Capital Markets | Buy |
| 2020-12-10 | Herabstufung | Jefferies | Buy → Hold |
| 2020-12-10 | Bestätigt | Needham | Buy |
| 2020-12-07 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-10-23 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2020-10-05 | Eingeleitet | BofA Securities | Buy |
| 2020-07-28 | Bestätigt | Needham | Buy |
| 2020-07-14 | Eingeleitet | SunTrust | Buy |
| 2020-06-15 | Bestätigt | Canaccord Genuity | Buy |
| 2020-03-05 | Eingeleitet | Stifel | Hold |
| 2020-02-03 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-11-19 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2019-11-12 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2019-08-01 | Eingeleitet | Jefferies | Buy |
| 2019-07-26 | Eingeleitet | Canaccord Genuity | Buy |
| 2019-06-10 | Eingeleitet | ROTH Capital | Buy |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2019-03-14 | Eingeleitet | William Blair | Mkt Perform |
| 2019-01-28 | Herabstufung | Goldman | Buy → Neutral |
| 2019-01-22 | Herabstufung | Citigroup | Neutral → Sell |
Alle ansehen
Crispr Therapeutics Ag Aktie (CRSP) Neueste Nachrichten
Top Executive Makes Bold Move With Fresh Crispr Therapeutics AG Stock Buy - TipRanks
CRISPR Therapeutics (NASDAQ:CRSP) Insider Purchases $49,703.68 in Stock - MarketBeat
Cathie Wood's Favorite Biotech Stock Is Under Pressure Amid Insider Sales And Slow Revenue Growth: Momentum Score Drops - Benzinga
CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: Here's Why - sharewise.com
CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
CRISPR Therapeutics (CRSP) Stock: Insider Sales Total $5.17 Million This Week - CoinCentral
CRISPR Therapeutics stock drops 9% after CEO sale filing — what CRSP investors watch next week - TechStock²
Did CEO Share Sale and Casgevy Rollout Just Shift CRISPR Therapeutics' (CRSP) Investment Narrative? - simplywall.st
CRISPR Therapeutics AG (CRSP) Stock Declines While Market Improves: Some Information for Investors - Yahoo Finance
CRISPR Therapeutics (NASDAQ:CRSP) Shares Down 5.8% on Insider Selling - MarketBeat
Retail Surge: Why is CRISPR Therapeutics AG stock going down2025 Short Interest & Consistent Profit Trading Strategies - mfd.ru
CRISPR Therapeutics (NASDAQ:CRSP) Price Target Cut to $89.00 by Analysts at Bank of America - MarketBeat
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
CRISPR Therapeutics stock in focus as shares cool premarket after 11% surge and CEO sale filing - TechStock²
CRISPR Therapeutics (NASDAQ:CRSP) CEO Samarth Kulkarni Sells 30,000 Shares of Stock - MarketBeat
Samarth Kulkarni Sells 60,000 Shares of CRISPR Therapeutics (NASDAQ:CRSP) Stock - MarketBeat
Casgevy Revenue Surge and Clinical Advancements Bolster CRISPR Therapeutics’ Market Position - StocksToTrade
Why Crispr Therapeutics Stock Is Climbing Again - TipRanks
BofA Securities Adjusts Price Target on CRISPR Therapeutics AG to $89 From $90, Maintains Buy Rating - marketscreener.com
Assessing CRISPR Therapeutics (CRSP) Valuation After Recent Share Price Weakness - Sahm
Understanding Momentum Shifts in (CRSP) - Stock Traders Daily
Can CRISPR Therapeutics AG reach all time highs this yearJuly 2025 Patterns & Reliable Intraday Trade Alerts - baoquankhu1.vn
CRISPR Therapeutics (CRSP) Soars 18% After $51-Million Insider Trading - MSN
Investors heavily search CRISPR Therapeutics AG (CRSP): Here is what you need to know - MSN
Is It Time To Reassess CRISPR Therapeutics (CRSP) After Recent Gene Editing Progress? - Sahm
Meme Stocks: Will CRISPR Therapeutics AG benefit from geopolitical trendsJuly 2025 Selloffs & AI Powered Market Entry Ideas - baoquankhu1.vn
Price Action: Is CRISPR Therapeutics AG showing insider buyingJuly 2025 Market Mood & Reliable Breakout Stock Forecasts - baoquankhu1.vn
Analysts Offer Insights on Healthcare Companies: Radnet (RDNT) and Crispr Therapeutics AG (CRSP) - The Globe and Mail
Nwam LLC Purchases 83,454 Shares of CRISPR Therapeutics AG $CRSP - MarketBeat
Crispr Therapeutics AG (CRSP) Gets a Buy from Bank of America Securities - The Globe and Mail
How CRISPR Therapeutics’ Expanding Gene-Editing Pipeline and CTX310 Trial Progress Will Impact CRSP Investors - Sahm
CRISPR Therapeutics (CRSP) is considered a good investment by brokers: Is that true? - MSN
Aug Summary: Can CRISPR Therapeutics AG maintain its current growth rateEarnings Risk Report & Real-Time Volume Trigger Notifications - baoquankhu1.vn
A Look At CRISPR Therapeutics (CRSP) Valuation As 2026 Gene Editing Milestones Come Into Focus - Sahm
Is CRISPR Therapeutics (CRSP) Using J.P. Morgan Spotlight to Recast Its Gene-Editing Leadership Story? - Sahm
CRISPR Therapeutics: Patience And Opportunity Through Volatility (NASDAQ:CRSP) - Seeking Alpha
Sumitomo Mitsui Trust Group Inc. Sells 251,163 Shares of CRISPR Therapeutics AG $CRSP - MarketBeat
Investors Heavily Search CRISPR Therapeutics AG (CRSP): Here is What You Need to Know - sharewise.com
Analysts Offer Insights on Healthcare Companies: Crispr Therapeutics AG (CRSP) and NeoGenomics (NEO) - The Globe and Mail
What's Driving the Market Sentiment Around CRISPR Therapeutics AG? - Benzinga
CRSP: Casgevy and next-gen gene editing platforms drive growth, with 2026 set as a pivotal year - TradingView — Track All Markets
2 Biotech Stocks That Could Soar This Year - Finviz
CRISPR Therapeutics (CRSP) Is Considered a Good Investment by Brokers: Is That True? - Finviz
CRSP: Regulatory Submissions for CASGEVY Expected by Mid-2026 - GuruFocus
CRSP Outlines Strategic Goals and Milestones for 2026 - GuruFocus
CRISPR Therapeutics Highlights Pipeline Advances in Gene-Edited Therapies - TipRanks
CRISPR Therapeutics Highlights Strategic Priorities and Anticipated 2026 Milestones - The Manila Times
CRISPR Therapeutics Outlines Strategic Priorities and Anticipated Milestones for 2026 - Quiver Quantitative
CRISPR Therapeutics stock (CRSP) drops into JPM week — what to watch next - TechStock²
CRISPR Therapeutics Reports Q3 2025 Financial Results - MSN
Avoiding Lag: Real-Time Signals in (CRSP) Movement - Stock Traders Daily
Finanzdaten der Crispr Therapeutics Ag-Aktie (CRSP)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.09%
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):